Quantcast
Reading Time: < 1 minute

Some 100,000 people in the United States suffer from sickle cell disease. A new move by the FDA may soon hopefully break down at least some of the barriers people face in accessing appropriate treatment for the disease.

The New York Times reports that the FDA is lending its endorsement to two forms of gene editing therapy one for humans and another considered relatively conventional gene editing therapy.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Bazaar Daily News
Translate »

Discover more from Bazaar Daily News

Subscribe now to keep reading and get access to the full archive.

Continue reading

Verified by MonsterInsights